Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

   Completed · Phase 1 · Healthy Volunteer

   NCT06742086 · AbbVie Inc. · 1 U.S. investigator

   $587,351research payments

2. ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

   Active, not recruiting · Metastatic Breast Cancer

   NCT05662345 · Menarini Silicon Biosystems, Inc. · 2 U.S. investigators

   $585,052research payments

3. A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

   Recruiting · Phase 3 · Type 2 Diabetes

   NCT06739122 · Eli Lilly and Company · 26 U.S. investigators

   $581,686research payments

4. A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

   Completed · Phase 1 · Renal Impairment

   NCT07165015 · Eli Lilly and Company · 2 U.S. investigators

   $580,576research payments

5. A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

   Active, not recruiting · Spasticity as Sequela of Stroke

   NCT06055725 · Ipsen Pharma Sas · 18 U.S. investigators

   $580,028research payments

6. A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

   Recruiting · Phase 3 · Migraine

   NCT05164172 · H. Lundbeck A S · 20 U.S. investigators

   $579,482research payments

7. Cenobamate Open-Label Extension Study for YKP3089C025

   Completed · Phase 3 · Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy

   NCT03961568 · Sk Life Science, Inc. · 22 U.S. investigators

   $576,382research payments

8. A Study of BGB-11417 in Participants With Myeloid Malignancies

   Recruiting · Phase 1, Phase 2 · Acute Myeloid Leukemia

   NCT04771130 · Beone Medicines USA, Inc. · 5 U.S. investigators

   $576,303research payments

9. IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

   Active, not recruiting · Phase 1, Phase 2 · Acute Myeloid Leukemia

   NCT04086264 · AbbVie Inc. · 8 U.S. investigators

   $575,040research payments

10. A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

    Enrolling by invitation · Phase 3 · PAH

    NCT03683186 · United Therapeutics Corporation · 45 U.S. investigators

    $574,924research payments

11. Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

    Active, not recruiting · Phase 1, Phase 2 · Acute Myeloid Leukemia

    NCT03793478 · Daiichi Sankyo Inc. · 19 U.S. investigators

    $573,480research payments

12. Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

    Completed · Phase 3 · Mantle-Cell Lymphoma

    NCT03112174 · AbbVie Inc. · 7 U.S. investigators

    $572,165research payments

13. A Study of DS-1471a In Subjects With Advanced Solid Tumors

    Terminated · Phase 1 · Advanced Solid Tumor

    NCT06074705 · Daiichi Sankyo Inc. · 3 U.S. investigators

    $571,538research payments

14. A Study of Modified mRNA Vaccines in Healthy Adults

    Completed · Phase 1 · SARS-CoV-2

    NCT05397223 · ModernaTX, Inc. · 3 U.S. investigators

    $568,472research payments

15. Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

    Terminated · Phase 3 · Antibody-mediated Rejection

    NCT03744910 · Csl Behring · 28 U.S. investigators

    $566,710research payments

16. A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

    Terminated · Phase 3 · Migraine

    NCT04396236 · Eli Lilly and Company · 63 U.S. investigators

    $566,672research payments

17. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    Recruiting · Phase 3 · Chronic Lymphocytic Leukemia

    NCT06943872 · Beone Medicines Ltd. · 9 U.S. investigators

    $563,925research payments

18. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

    Active, not recruiting · Phase 3 · Ulcerative Colitis (UC)

    NCT03006068 · AbbVie Inc. · 45 U.S. investigators

    $562,657research payments

19. An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

    Completed · Phase 4 · Primary Immunodeficiency

    NCT07076446 · Csl Behring · 7 U.S. investigators

    $561,075research payments

20. Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

    Recruiting · Phase 2 · Focal Segmental Glomerulosclerosis

    NCT05003986 · Travere Therapeutics, Inc. · 18 U.S. investigators

    $554,494research payments

21. Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

    Completed · Phase 3 · Atopic Dermatitis

    NCT02612454 · Regeneron Pharmaceuticals, Inc. · 24 U.S. investigators

    $553,050research payments

22. DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

    Recruiting · Phase 2 · Breast Cancer

    NCT06176261 · Daiichi Sankyo Inc. · 0 U.S. investigators

    $550,682research payments

23. A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

    Recruiting · Phase 2 · Hidradenitis Suppurativa

    NCT06524635 · AbbVie Inc. · 2 U.S. investigators

    $549,478research payments

24. A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

    Active, not recruiting · Phase 2 · Glioma

    NCT06413706 · Eli Lilly and Company · 14 U.S. investigators

    $549,371research payments

25. Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

    Completed · Phase 2, Phase 3 · Irritability Associated With Autism Spectrum Disorder

    NCT05523895 · Acadia Pharmaceuticals Inc · 18 U.S. investigators

    $549,163research payments

26. Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.

    Recruiting · Phase 4 · Diabetic Foot Ulcer (DFU)

    NCT07209475 · Royal Biologics, Inc. · 11 U.S. investigators

    $548,680research payments

27. Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

    Recruiting · Phase 3 · Intermediate Risk Non-Muscle Invasive Bladder Cancer

    NCT06510374 · Ferring Pharmaceuticals As · 21 U.S. investigators

    $546,844research payments

28. A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

    Withdrawn · Phase 2 · Obesity

    NCT06901349 · Eli Lilly and Company · 25 U.S. investigators

    $546,057research payments

29. Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

    Recruiting · Phase 2, Phase 3 · Duchenne Muscular Dystrophy

    NCT03373968 · Itf Therapeutics LLC · 9 U.S. investigators

    $543,606research payments

30. A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

    Recruiting · Phase 2 · Focal Segmental Glomerulosclerosis

    NCT06500702 · Genzyme Corporation · 15 U.S. investigators

    $538,301research payments

31. HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

    Active, not recruiting · Phase 3 · Nonsquamous Non-small Cell Lung Cancer

    NCT05338970 · Daiichi Sankyo Inc. · 18 U.S. investigators

    $538,226research payments

32. Open-label Trial in Parkinson's Disease (PD)

    Completed · Phase 3 · Parkinson Disease

    NCT04760769 · AbbVie Inc. · 36 U.S. investigators

    $538,223research payments

33. 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

    Completed · Phase 2 · Irritable Bowel Syndrome With Constipation (IBS-C)

    NCT06553547 · Ardelyx, Inc. · 10 U.S. investigators

    $537,957research payments

34. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

    Active, not recruiting · Phase 3 · Crohn's Disease

    NCT03345823 · AbbVie Inc. · 37 U.S. investigators

    $537,176research payments

35. A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

    Terminated · Phase 1, Phase 2 · Metastatic Prostate Cancer

    NCT04179864 · Epizyme, Inc. · 12 U.S. investigators

    $535,018research payments

36. A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

    Active, not recruiting · Phase 2, Phase 3 · Hepatocellular Carcinoma

    NCT06109272 · AbbVie Inc. · 10 U.S. investigators

    $533,788research payments

37. Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

    Terminated · Phase 2 · Ulcerative Colitis

    NCT05785715 · AbbVie Inc. · 15 U.S. investigators

    $530,447research payments

38. Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    Recruiting · Phase 2 · Idiopathic Pulmonary Fibrosis

    NCT05571059 · Cumberland Pharmaceuticals, Inc. · 13 U.S. investigators

    $529,985research payments

39. Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

    Approved for marketing · Hypoparathyroidism

    NCT05654701 · Ascendis Pharma Endocrinology Inc · 51 U.S. investigators

    $528,918research payments

40. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Recruiting · Phase 2 · Non-Small Cell Lung Cancer

    NCT06568939 · AbbVie Inc. · 25 U.S. investigators

    $527,982research payments

41. (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

    Completed · Phase 2 · Advanced Systemic Mastocytosis

    NCT03580655 · Blueprint Medicines Corporation · 11 U.S. investigators

    $523,025research payments

42. A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Active, not recruiting · Phase 3 · Diffuse Large B-Cell Lymphoma

    NCT06508658 · AbbVie Inc. · 14 U.S. investigators

    $522,833research payments

43. Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

    Active, not recruiting · Phase 2 · Relapsed/Refractory Peripheral T-Cell Lymphoma

    NCT04703192 · Daiichi Sankyo Inc. · 16 U.S. investigators

    $521,701research payments

44. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

    Active, not recruiting · Phase 3 · Psoriatic Arthritis (PsA)

    NCT03671148 · AbbVie Inc. · 28 U.S. investigators

    $519,941research payments

45. TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

    Terminated · Phase 2 · Head and Neck Neoplasms

    NCT05980598 · Ascendis Pharma Endocrinology Inc · 17 U.S. investigators

    $519,694research payments

46. Pan Tumor Rollover Study

    Recruiting · Phase 2 · Cancer

    NCT03899155 · E.r. Squibb & Sons, L.l.c. · 28 U.S. investigators

    $518,201research payments

47. Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

    Active, not recruiting · Chronic Rhinosinusitis With Nasal Polyposis

    NCT04959448 · Regeneron Pharmaceuticals, Inc. · 42 U.S. investigators

    $517,123research payments

48. ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

    Active, not recruiting · Phase 3 · Myelodysplastic Syndromes

    NCT05949684 · E.r. Squibb & Sons, L.l.c. · 15 U.S. investigators

    $515,926research payments

49. Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

    Recruiting · Parkinson's Disease

    NCT02071134 · Boston Scientific Corporation · 19 U.S. investigators

    $515,404research payments

50. A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

    Terminated · Phase 1 · Diffuse Large B Cell Lymphoma (DLBCL)

    NCT05169489 · Regeneron Pharmaceuticals, Inc. · 3 U.S. investigators

    $513,063research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.